UNSPSC 51173225: Dehydrocholic acid/docusate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.

UNSPSC 51173225 Dehydrocholic acid/docusate is a Commodity code encompassing pharmaceutical products used in specimen collection, drug testing, and broader pharmacy benefit programs across state and local jurisdictions. The recent opportunities under this code reflect state and local demand for both specialty pharmaceuticals supporting criminal justice and correctional programs and generic multi-source pharmaceuticals serving broader health and human services procurement. State and local buyers include county corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating acquisitions across participating jurisdictions. The scope of work ranges from specimen collection and drug testing consumables (reagents, screening and confirmation materials) used in offender monitoring programs to generic pharmaceutical supply through established wholesaler distribution channels.

Collin County (Texas) issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a July 23, 2026 response deadline, seeking immunoassay screening and LC/MS/MS or GC/MS confirmation testing across two sites serving approximately 25,031 annual tests, with an estimated contract value of $600,000 over two years plus optional renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling exploratory procurement strategy development ahead of formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with award effective July 1, 2026. Recent activity concentrates in Texas and Minnesota, with MMCAP's procurement scope extending to Oregon and other participating cooperative members.